



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/44

Date: 13th August 2026

To,

The Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: Intimation for approval to acquire shares of Sudarshan Maven Pharma Private Limited

Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have at their meeting held on 12th August 2026, inter-alia, approved divestment of 209,100 equity shares of Rs.10/- each of Ishwari Healthcare Private Limited ('Ishwari Healthcare') (CIN: U85100MH2011PTC212867), subsidiary of the Company, equivalent to 51.00% of the paid-up equity share capital of Ishwari Healthcare. Upon completion of the divestment, Ishwari Healthcare would cease to be subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given in Annexure-A.

You are requested to take the same on record.

Thanks & Regards,

Yours faithfully,

For, **Sudarshan Pharma Industries Limited**


Hemal Mehta
Chairman & Managing Director





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

Annexure-A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given below:

SL NO	Details to be Provided	Information
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Name: Ishwari Healthcare Private Limited As on 31 st March 2026 Authorised Share Capital: Rs.50 Lakhs Paid Up Share Capital: Rs.41 Lakhs Total Income: Rs.746.21 Lakhs
2	Date on which the agreement for sale has been entered into;	The Company has not executed any agreement for divestment of the equity shares of Ishwari Healthcare held by the Company.
3	the expected date of completion of sale / disposal	31 st December 2026
4	consideration received from such sale / disposal;	Divestment amount shall be decided upon completion of valuation of Ishwari Healthcare.
5	brief details of buyers and whether any of the buyers belong to the promoter / promoter group / group companies. If yes, details thereof;	The Board of Directors has approved the divestment of the equity shares of Ishwari Healthcare held by the Company and delegated powers to the management to find a buyer for divestment at the most competitive price.
6	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Not Applicable as the buyer is yet to be identified.
7	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not Applicable Provisions of Regulation 37A are not applicable as the subsidiary does not fall under the definition of "Undertaking" as defined under clause (a) of sub-section (1) of section 180 of the Companies Act, 2013.





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

8	additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable
---	--	----------------

For, **Sudarshan Pharma Industries Limited**

Hemal Mehta
Chairman & Managing Director

